MedPath

FDA Approves First Brain-Injected Gene Therapy Kebilidi for AADC Deficiency

• The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, the first of its kind to be injected directly into the brain. • Kebilidi is designed to boost AADC enzyme production in the brain, restoring dopamine levels and improving motor function in children and adults with the rare genetic disorder. • The approval was based on clinical trial data from 13 children, with ongoing studies required for full FDA approval, and common side effects include dyskinesia, anemia, and post-injection complications. • AADC deficiency is a rare genetic disorder impacting physical, mental, and behavioral health from infancy, leading to severe disabilities and reduced lifespan due to impaired dopamine production.

The FDA has granted accelerated approval for Kebilidi (eladocagene exuparvovec), a groundbreaking gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. This marks the first gene therapy approved in the United States that is administered directly into the brain. The therapy is indicated for both children with fully developed skulls and adults affected by this rare genetic disorder.
AADC deficiency is a rare genetic condition that impairs the body's ability to produce dopamine, a critical neurotransmitter. This deficiency manifests early in life, leading to significant physical, mental, and behavioral impairments, including severe disabilities and a shortened lifespan. Patients may also experience oculogyric crises, characterized by painful, seizure-like episodes.
Kebilidi works by delivering a functional gene directly into a specific region of the brain, thereby increasing AADC enzyme production and restoring dopamine synthesis. This aims to improve motor-related symptoms and overall neurological function. The gene therapy is administered via a surgical procedure performed by specialized brain surgeons at designated centers.
The FDA's approval was based on data from an ongoing clinical trial involving 13 children with AADC deficiency. While the therapy demonstrated safety and effectiveness in this patient group, PTC Therapeutics, the manufacturer of Kebilidi, notes that long-term follow-up studies are necessary to confirm the durability of the treatment's benefits and to secure full FDA approval.
Common side effects observed during the clinical trial included involuntary movements (dyskinesia), anemia, fever, low blood pressure, excessive salivation, sleep disturbances, and decreased levels of certain minerals. The surgical procedure itself carries risks such as cerebrospinal fluid leaks, bleeding in the brain, inflammation, stroke, and infection. These risks necessitate careful patient selection and monitoring.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain, for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in both children and adults, addressing the full spectrum of disease severity.
Kebilidi is the first gene therapy approved in the U.S. that is directly administered to the brain, offering a novel approach to treating this rare neurological disorder.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating Aromatic L-Amino Acid Decarboxylase (AADC) deficiency in adults and children.
Kebilidi, an adeno-associated virus vector-based gene therapy, is the first FDA-approved treatment of its kind for this rare genetic disorder affecting neurotransmitter production.

FDA Approves PTC Therapeutics' Kebillidi, First Gene Therapy for AADC Deficiency

The FDA has approved Kebillidi (eladocagene exuparvovec-tneq) from PTC Therapeutics, a gene therapy for both adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency.
Kebillidi's approval is based on a single-arm study demonstrating significant motor milestone gains in a majority of treated pediatric patients compared to untreated individuals.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the U.S.
Kebilidi is administered directly into the brain and replaces the mutated DDC gene with a functional version, restoring dopamine and serotonin production in both adults and children.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq) from PTC Therapeutics, the first gene therapy for Aromatic L-amino acid decarboxylase (AADC) deficiency.
Kebilidi is an adeno-associated virus vector-based gene therapy designed for both adult and pediatric patients suffering from AADC deficiency, administered via neurosurgical infusion.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.
Kebilidi is the first gene therapy approved in the U.S. that involves direct administration into the brain, offering a novel approach to treating AADC deficiency.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has approved eladocagene exuparvovec-tneq (Kebilidi) as the first gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency in adults and pediatric patients.
Kebilidi, administered via infusions into the brain, facilitates AADC expression and dopamine production, addressing motor, attention, learning, and memory impairments.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first such treatment approved in the U.S.
Kebilidi delivers a functional copy of the DDC gene to brain cells, restoring the missing AADC enzyme and enabling dopamine production in both children and adults.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.
Kebilidi, developed by PTC Therapeutics, is the first gene therapy approved in the U.S. that is directly administered to the brain via a stereotactic surgical procedure.

FDA Approves Kebilidi Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating AADC deficiency in both children and adults.
Kebilidi, a gene replacement therapy, is administered directly into the brain to restore dopamine production, addressing the underlying genetic defect.

Reference News

[1]
First Brain-Injected Gene Therapy Approved by FDA - WebMD
webmd.com · Nov 18, 2024

FDA fast-tracks approval for Kebilidi, a gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, the fir...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy